ChromaDex, Inc.

234 articles about ChromaDex, Inc.

• ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea

  6/2/2022

  ChromaDex Corp. announced a partnership with Juvenis to conduct cross-border sales of Tru Niagen® in South Korea.

• ChromaDex to Present at the LD Micro Invitational

  6/1/2022

  ChromaDex Corp. announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the 12th annual Invitational.

• ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China

  5/19/2022

  The signed agreement establishes beachhead to broadly market and distribute Tru Niagen® to Mainland China’s aging population ChromaDex Corp. a global bioscience company dedicated to healthy aging, announced it has entered into an agreement to establish a joint venture through its wholly owned subsidiary ChromaDex Asia Limited.

• ChromaDex Corporation Reports First Quarter 2022 Financial Results

  5/12/2022

  ChromaDex Corp. announced financial results for the first quarter of 2022.

• ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors

  4/22/2022

  ChromaDex Corp. (NASDAQ: CDXC) today announced that it has appointed two new members to its Board of Directors: Kristin Patrick, Executive Vice President and Chief Marketing Officer of Claire's Inc., and Ann Cohen, Executive Vice President and Chief Financial Officer of The Institute of Internal Auditors (The IIA).

• ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio

  4/6/2022

  ChromaDex Launches Tru Niagen ® Immune, Further Expanding Innovative Product Portfolio.

• ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations

  3/16/2022

  ChromaDex Corp. announced that it was granted an additional continuation patent, U.S. Patent No. 11,274,117, adding to its global patent portfolio surrounding nicotinamide riboside and other nicotinamide adenine dinucleotide precursors.

• ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results

  3/9/2022

  Total net sales of $67.4 million for the full year, up 14% from the prior year, with $56.7 million from Tru Niagen® and gross margin of 61.5%.

• ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study Analyzing the Promising Effect of Nicotinamide Riboside (NR) Supplementation in Patients with Parkinson’s Disease (PD)

  3/2/2022

  ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study, as reported in the peer-reviewed journal Cell Metabolism.

• ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside

  2/9/2022

  ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted a continuation patent, adding to its global patent portfolio surrounding nicotinamide riboside.

• ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation

  1/25/2022

  ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen® (patented nicotinamide riboside, or “NR”) ingredient with promising, peer-reviewed findings reported in the Journal of Clinical Investigation.

• ChromaDex and Designs for Health Partner for New Product Development on Niagen®

  1/20/2022

  ChromaDex Corp. announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners.

• ChromaDex Corporation Reports Third Quarter 2021 Financial Results

  11/3/2021

  ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2021.

• ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)

  10/18/2021

  ChromaDex Corp. announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movement Disorders, conducted by Michèl A.A.P. Willemsen MD, PhD of Radboud University Medical Center.

• ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021

  10/13/2021

  ChromaDex Corp. announced that it will hold a conference call on Wednesday, Nov. 3, 2021 at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sep. 30, 2021.

• ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)

  9/20/2021

  ChromaDex Corp. announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen® in various health outcomes.

• ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge’s Ruling in Patent Infringement Lawsuit

  9/15/2021

  ChromaDex Corp. (NASDAQ:CDXC) issued the following statement: ChromaDex announced today plans to appeal a September 14 decision granting a Motion for Summary Judgment (MSJ) in its lawsuit for patent infringement against Elysium Health, Inc. (“Elysium”) in the United States District Court for the District of Delaware. ChromaDex licenses U.S. Patent No. 8,383,086

• ChromaDex Corporation Reports Second Quarter 2021 Financial Results

  8/3/2021

  ChromaDex Corp. announced financial results for the second quarter of 2021.

• ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

  7/20/2021

  ChromaDex Corp. announced that it will hold a conference call on Tues., August 3, 2021 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2021.

• ChromaDex Shares Research Findings from the ChromaDex External Research Program (CERP™)

  6/16/2021

  ChromaDex Corp. announced the results of four recently published preclinical studies, highlighting new findings for its patented nicotinamide riboside healthy aging nutrient.